These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15857288)

  • 1. Monoclonal antibodies targeting the epidermal growth factor receptor.
    Bianco R; Daniele G; Ciardiello F; Tortora G
    Curr Drug Targets; 2005 May; 6(3):275-87. PubMed ID: 15857288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
    Ciardiello F; Tortora G
    Clin Cancer Res; 2001 Oct; 7(10):2958-70. PubMed ID: 11595683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-epidermal growth factor receptor drugs in cancer therapy.
    Ciardiello F; Tortora G
    Expert Opin Investig Drugs; 2002 Jun; 11(6):755-68. PubMed ID: 12036420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.
    Ciardiello F; De Vita F; Orditura M; De Placido S; Tortora G
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):501-14. PubMed ID: 14662002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy.
    Herbst RS; Shin DM
    Cancer; 2002 Mar; 94(5):1593-611. PubMed ID: 11920518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy.
    Tortora G; Gelardi T; Ciardiello F; Bianco R
    Int J Biol Markers; 2007; 22(1 Suppl 4):S47-52. PubMed ID: 17520581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with monoclonal antibodies to epidermal growth factor receptor.
    Calvo E; Rowinsky EK
    Curr Oncol Rep; 2005 Mar; 7(2):96-103. PubMed ID: 15717942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment.
    Capdevila J; Elez E; Macarulla T; Ramos FJ; Ruiz-Echarri M; Tabernero J
    Cancer Treat Rev; 2009 Jun; 35(4):354-63. PubMed ID: 19269105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.
    Foon KA; Yang XD; Weiner LM; Belldegrun AS; Figlin RA; Crawford J; Rowinsky EK; Dutcher JP; Vogelzang NJ; Gollub J; Thompson JA; Schwartz G; Bukowski RM; Roskos LK; Schwab GM
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):984-90. PubMed ID: 14967460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The epidermal growth factor receptor as a target for cancer therapy.
    Mendelsohn J
    Endocr Relat Cancer; 2001 Mar; 8(1):3-9. PubMed ID: 11350723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents.
    Ciardiello F
    Drugs; 2000; 60 Suppl 1():25-32; discussion 41-2. PubMed ID: 11129169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives.
    Zhu Z
    Acta Pharmacol Sin; 2007 Sep; 28(9):1476-93. PubMed ID: 17723181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.
    Bianco R; Troiani T; Tortora G; Ciardiello F
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S159-71. PubMed ID: 16113092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of an anti-epidermal growth factor receptor in treating cancer.
    Waksal HW
    Cancer Metastasis Rev; 1999; 18(4):427-36. PubMed ID: 10855786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor biology (IMC-C225).
    Kim ES; Khuri FR; Herbst RS
    Curr Opin Oncol; 2001 Nov; 13(6):506-13. PubMed ID: 11673692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER.
    Moradi-Kalbolandi S; Hosseinzade A; Salehi M; Merikhian P; Farahmand L
    J Pharm Pharmacol; 2018 Jul; 70(7):841-854. PubMed ID: 29574771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why the epidermal growth factor receptor? The rationale for cancer therapy.
    Baselga J
    Oncologist; 2002; 7 Suppl 4():2-8. PubMed ID: 12202782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
    Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
    Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.